Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Resverlogix Corp. T.RVX

Alternate Symbol(s):  T.RVX.W.A | RVXCF

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.


Recent & Breaking News (TSX:RVX)

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014

Business Wire August 11, 2014

RVX-208 Reduces Major Adverse Cardiovascular Events (MACE) Significantly in Patients with Diabetes Mellitus

Canada NewsWire July 23, 2014

Microcap Report: Resverlogix (T.RVX), Virtutone Networks (V.VFX) active

Stockhouse Editorial July 4, 2014

Resverlogix (T.RVX) ups Citibank loan by $30.0 million and shares bump 10%

Stockhouse Editorial July 4, 2014

Resverlogix Secures an Additional $30 million from Citibank Loan

Canada NewsWire July 3, 2014

Resverlogix Closes $2.3 million Private Placement

Canada NewsWire June 11, 2014

Leading Life Science Publication SciBX Highlights RVX-208

Canada NewsWire May 21, 2014

Cleveland Clinic Presents RVX-208 Data at American College of Cardiology (ACC) Conference in Washington DC March 31, 2014

Canada NewsWire March 31, 2014

Resverlogix Update

Canada NewsWire March 17, 2014

Resverlogix Conference Call & Webcast Announcement

Canada NewsWire February 6, 2014

Resverlogix (T.RVX) jumps 45% on positive RVX-208 trial findings

Gaalen Engen January 15, 2014

Resverlogix Announces Combined RVX-208 findings from SUSTAIN & ASSURE Phase 2b Trials

Canada NewsWire January 15, 2014

Resverlogix (T.RVX) up 15% on industry publication recognition

Gaalen Engen January 3, 2014

Publications Confirm RVX-208 is a Unique Selective BET Bromodomain Antagonist

Canada NewsWire January 2, 2014

Resverlogix Completes Enrollment of Phase 2 Clinical Trial of RVX-208 in Patients with Pre-Diabetes Mellitus

Canada NewsWire December 23, 2013

Resverlogix digs deeper in to trial data, finds reason for poor July results

Chris Parry November 4, 2013

Resverlogix Announces Two New Findings from the ASSURE Trial Relating to Inflammation and Plaque Vulnerability

Canada NewsWire November 4, 2013

InvestorsGuru.com 32 Filtered Mid-Day Market Movers Recap

Investors Guru September 7, 2013

Further Analysis of the ASSURE Data Finds a Responder Group for RVX-208 with Statistically Significant Regression of Coronary Atherosclerosis

PR Newswire September 3, 2013

Further Analysis of the ASSURE Data Finds a Responder Group for RVX-208 with Statistically Significant Regression of Coronary Atherosclerosis

Canada NewsWire September 3, 2013